Elite Pharmaceuticals, Inc.·Healthcare

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) and Rafael (NYSE: RFL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Profitability This table compares Elite Pharmaceuticals and Rafael's

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.40 and traded as low as $0.3606. Elite Pharmaceuticals shares last traded at $0.3753, with a volume of 166,781 shares trading hands. Elite Pharmaceuticals

Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options including immediate-release opioids.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) shares passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.52 and traded as low as $0.37. Elite Pharmaceuticals shares last traded at $0.3704, with a volume of 1,179,674 shares trading hands. Elite

ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.

Elite Pharmaceuticals, Inc. (ELTP) Q3 2026 Earnings Call Prepared Remarks Transcript
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Healthcare
Drug Manufacturers - Specialty & Generic
64
2000-02-24
0.44